Strategically Designed Panel for the Optimal Management of Thyroid Nodules. And now, newly added TERT and ALK mutations can reliably help to predict aggressive biological features of thyroid cancer.
Interpace Diagnostics is the only company that offers:
In-Network Access for More Than 3 Million Members Parsippany, NJ, April 27, 2020 (GLOBE NEWSWIRE) — Interpace Biosciences (NASDAQ: IDXG) announced today that its subsidiary, Interpace Diagnostics, has entered into
Parsippany, NJ, March 11, 2020 (GLOBE NEWSWIRE) — Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) — Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has
Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2019 Interpace Biosciences, Inc.™ All rights reserved.
